

Amir Sabet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9922744/publications.pdf>

Version: 2024-02-01

28
papers

1,242
citations

430874

18
h-index

501196

28
g-index

29
all docs

29
docs citations

29
times ranked

1332
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of peptide receptor radionuclide therapy with ¹⁷⁷ Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 925-933.	6.4	165
2	Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-Octreotate. <i>Journal of Nuclear Medicine</i> , 2014, 55, 183-190.	5.0	158
3	Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-Octreotate. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1857-1861.	5.0	128
4	Specific efficacy of peptide receptor radionuclide therapy with ¹⁷⁷ Lu-octreotate in advanced neuroendocrine tumours of the small intestine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1238-1246.	6.4	91
5	Outcome and toxicity of salvage therapy with ¹⁷⁷ Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 205-210.	6.4	87
6	Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 459-466.	6.4	84
7	Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with ¹⁷⁷ Lu-octreotate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 505-510.	6.4	76
8	Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by ¹⁸ F-FDG PET: Feasibility of a Metabolic Grading System. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1260-1266.	5.0	76
9	Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-Octreotate. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1197-1203.	5.0	59
10	Early post-treatment FDG PET predicts survival after ⁹⁰ Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 370-376.	6.4	52
11	¹⁷⁷ Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1075-1085.	6.4	37
12	Significance of Oral Administration of Sodium Perchlorate in Planning Liver-Directed Radioembolization. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1063-1067.	5.0	29
13	Successful radiopeptide targeting of metastatic anaplastic meningioma: Case report. <i>Radiation Oncology</i> , 2011, 6, 94.	2.7	27
14	Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing ¹⁷⁷ Lu-PSMA-617 radioligand therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 103-112.	6.4	27
15	Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy. <i>European Radiology</i> , 2017, 27, 966-975.	4.5	25
16	Efficacy of peptide receptor radionuclide therapy with Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 7, 74-83.	1.0	23
17	Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing ⁹⁰ Y-microsphere radioembolization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1531-1541.	2.5	20
18	Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 3, 437-45.	1.0	18

#	ARTICLE	IF	CITATIONS
19	Hematologic safety of ¹⁷⁷ Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2021, 11, 61.	2.5	16
20	Response Assessment and Prediction of Progression-Free Survival by ⁶⁸ Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy. <i>Biomolecules</i> , 2021, 11, 1099.	4.0	14
21	Safety and Efficacy of ¹⁷⁷ Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing ²²³ Radium-Dichloride. <i>Cancers</i> , 2022, 14, 557.	3.7	7
22	Survival After Accidental Extrahepatic Distribution of Y90 Microspheres to the Mesentery During a Radioembolization Procedure. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 954-957.	2.0	6
23	Salvage Radioligand Therapy with Repeated Cycles of ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement. <i>Cancers</i> , 2021, 13, 4017.	3.7	5
24	Outcome of ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer. <i>Cancers</i> , 2021, 13, 4193.	3.7	5
25	May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (¹⁸⁸ Re)-HEDP treatment in progressive bone metastases after (¹⁷⁷ Lu)-octreotate. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 4, 80-8.	1.0	4
26	Factors predicting outcome of G1/2 ⁺ GEP NET after PRRT with Lu ¹⁷⁷ -octreotate.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14565-e14565.	1.6	1
27	Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE. <i>Pharmaceuticals</i> , 2021, 14, 1022.	3.8	1
28	Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer. <i>Current Oncology</i> , 2022, 29, 4012-4019.	2.2	1